ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Atara Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$8.96−0.22 (-2.40%)

Close on Oct 19, 2026

Market cap: $134.70M
P/E (TTM): 3.5
Dividend yield: –

Atara Biotherapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	121	129	8.57	64	–	–	–	–	–	–	–	–	–
Research & Development	37	151	225	273	282	245	216	167	81	57	42	15	4.31
General & Administrative	26	40	51	72	79	64	80	70	40	25	17	13	3.76
Operating Expenses	–	–	–	344	361	309	296	237	122	81	58	28	8.62
Total Costs & Expenses	85	212	285	344	–	–	–	–	–	–	–	–	–
Operating Income	36	-83	-276	-281	-340	-309	-296	-237	-122	-81	-58	-28	-8.62
Interest Expense	3.79	4.62	5.29	0.37	–	–	–	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	0.13	0.01
Other Non-Operating Income	-0.03	0.53	-0.25	-0.70	0.37	2.45	4.72	6.37	2.03	2.20	1.22	0.13	0.01
Merger & Restructuring Charges	13	5.11	6.73	5.96	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	–
Gain (Loss) on Investments	–	–	–	50	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	0	50	0	0	-1.03	0	0	–	–	–	–
Pretax Income	33	-85	-276	-228	-340	-307	-291	-231	-120	-79	-57	-28	-8.60
Income Tax Expense	0.03	-0.01	0.02	0.01	0.05	0.02	0.01	-0.04	-0.01	0.01	-0.01	-0.03	0.17
Net Income incl. Noncontrolling Interests	33	-85	-276	-228	-340	-307	-291	-231	-119	-79	–	–	–
Net Income	33	-85	-276	-228	-340	-307	-291	-231	-119	-79	-57	-28	-8.77
EPS (Basic)(per share)	2.61	-11.41	-65.19	-56.00	-90.75	-103.75	-141.75	-131.75	-100.00	-68.75	–	–	–
EPS (Diluted)(per share)	2.57	-11.41	-65.19	-56.00	-90.75	-103.75	-141.75	-131.75	-100.00	-68.75	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	13	7.49	4.24	4.08	3.75	2.96	2.05	1.75	1.19	1.15	1.02	0.20	0.04
Shares Outstanding (Diluted, Weighted)(shares)	13	7.49	4.24	4.08	3.75	2.96	2.05	1.75	1.19	1.15	1.02	0.20	0.04
EBITDA	38	-78	-271	-275	-331	-301	-289	-233	-121	-81	-58	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -229.7%
Net margin: -269.4%
Return on equity, FY2025: -48.1%

Financial strength

Current ratio: 1.98
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 47.0%

Valuation

P/E ratio: 3.5
Price to sales: 21.75
Price to book: –
Dividend yield: –